Patience, patience. Then courage, courage.
I am astonished at the aggressive ignorance of the hedge funds that are involved.
It suggests FDA tendency to approve drugs for Alzheimer's Disease--including marginal and questionable ones such as Acadia's drug. That's why it seems positive for Axovant, that's all.
thus doubling the cost of research & development. Failure of either one can lead to severe dilution of present stockholders.